CureZone   Log On   Join
Enhertu: Breast cancer treatment
rajupharma Views: 74
Published: 11 months ago

Enhertu: Breast cancer treatment

The FDA-approved medicine Enhertu is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Enhertu is a sterile, white to yellowish-white, preservative-free lyophilized powder in single-dose vials in 100 mg to administer intravenously. The active ingredient in the medicine is Trastuzumab Deruxtecan with inactive ingredients L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose. The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology, and the topoisomerase inhibitor and linker are produced by chemical synthesis. Enhertu for injection is a white to yellowish-white lyophilized powder. The common side-effects of Enhertu are nausea, tiredness, vomiting, hair loss, constipation, decreased appetite, low red blood cell counts, low white blood cell counts, diarrhoea, cough, and low platelet counts.
The price of Enhertu is reasonable, and it is available among numerous wholesalers of Enhertu in India. For more details, please ring us on 18008891064.

Printer-friendly version of this page Email this message to a friend
Alert Moderators
Report Spam or bad message  Alert Moderators on This GOOD Message

This Forum message belongs to a larger discussion thread. See the complete thread below. You can reply to this message!


Donate to CureZone

CureZone Newsletter is distributed in partnership with

Contact Us - Advertise - Stats

Copyright 1999 - 2023

0.906 sec, (1)